Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer

J Urol. 1995 Aug;154(2 Pt 1):414-21. doi: 10.1097/00005392-199508000-00024.


Purpose: We studied the role of p53 tumor suppressor gene alteration in prostate cancer progression by demonstrating a difference in abnormal p53 findings between early and hormone refractory disease.

Materials and methods: The study included p53 immunohistochemistry of 26 archival transurethral resection specimens from patients with radiation recurrent and hormone refractory disease, 27 untreated primary tumors and 8 untreated metastatic lesions. p53 mutation analysis of tumor deoxyribonucleic acid (DNA) from microdissected specimens was done by cold single strand conformational polymorphism and DNA sequencing.

Results: Elevated p53 protein was present in 16 of 17 hormone refractory specimens (94%), 4 of 8 untreated metastatic tumors (50%) and 6 of 27 primary untreated tumors (22%). DNA analysis of representative specimens with elevated p53 confirmed p53 gene alterations in 9 of 11 cases (82%).

Conclusions: Our study revealed a clear progression of increased p53 alteration from untreated primary to hormone refractory disease (p < 0.00005).

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Base Sequence
  • DNA Mutational Analysis
  • DNA, Neoplasm / analysis
  • Genes, p53 / genetics*
  • Humans
  • Immunohistochemistry
  • Male
  • Molecular Sequence Data
  • Polymorphism, Single-Stranded Conformational
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / therapy
  • Treatment Failure


  • DNA, Neoplasm